This is a 2-part study where all participants will receive bepirovirsen. The study will measure how much bepirovirsen from a single dose gets into the blood, and how long it stays in the blood. The purpose of the study is to understand if blood levels of bepirovirsen are different in adults with kidney disease compared to healthy adults who do not have kidney disease.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
32
Bepirovirsen will be administered.
GSK Investigational Site
Tampa, Florida, United States
RECRUITINGPlasma Area Under the Concentration Time Curve From Time Zero (Pre-Dose) Extrapolated to Infinite Time [AUC(0-∞)] of Bepirovirsen
Time frame: Up to Day 50
Maximum Observed Concentration (Cmax) of Bepirovirsen
Time frame: Up to Day 50
Plasma Area Under the Concentration Time Curve From Time Zero (Pre-Dose) to 24 hours [AUC(0-24)] of Bepirovirsen
Time frame: Up to 24 hours
Plasma Area Under the Concentration Time Curve From Time Zero (Pre-Dose) to 168 hours (Day 8) [AUC(0-168)] of Bepirovirsen
Time frame: Up to 168 hours
Observed Concentration of Bepirovirsen on Day 8
Time frame: At Day 8
Apparent Terminal Phase Half-life (t1/2) of Bepirovirsen
Time frame: Up to Day 50
Apparent Clearance (CL/F) of Bepirovirsen
Time frame: Up to Day 50
Time of Occurrence of Cmax (Tmax) of Bepirovirsen
Time frame: Up to Day 50
Apparent Terminal Phase Volume of Distribution (Vz/F) of Bepirovirsen
Time frame: Up to Day 50
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.